Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study

Daily glatiramer acetate (GA) 20 mg/1.0 mL is a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). To reduce the occurrence of injection pain and local injection site reactions (LISRs), a reduced volume formulation of GA was developed. This study compared pain and LISRs after in...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, G., Meyer, D., Herrman, C. E., Sheppard, C., Murray, R., Fox, E. J., Mathena, J., Conner, J., Buck, P. O.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977058/
https://www.ncbi.nlm.nih.gov/pubmed/20953791
http://dx.doi.org/10.1007/s00415-010-5779-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977058/
https://www.ncbi.nlm.nih.gov/pubmed/20953791
http://dx.doi.org/10.1007/s00415-010-5779-x

Ejemplares similares